TEST:

Cologuard®

The study found poor follow-up adherence, with only 44% completing colonoscopy and a high false positive rate with just 38.5% of positive Cologuard® results showing significant lesions. These findings emphasize the need for better patient education, streamlined care pathways, and improved communication to enhance follow-up compliance.

P=N/A, N=100, Active, not recruiting, University of California, San Diego | Trial completion date: Apr 2025 --> Dec 2025

''Exact Sciences Corp...today announced new data being presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 24–29, 2025, at the Phoenix Convention Center in Phoenix, Arizona. The company’s research showcases leadership in advancing colorectal cancer (CRC) screening through high-quality science, real-world evidence, and innovations that improve screening adherence and access across diverse patient populations.''

This project demonstrates that practical, multifaceted, low-cost strategies of provider-focused education and patient-directed digital outreach can significantly improve Cologuard usage, ultimately leading to an increase in CRC screening completion rates. Sustained reinforcement and improvement in kit return will be a key to future improvements.

P=N/A, N=150000, Active, not recruiting, Exact Sciences Corporation | Trial completion date: Dec 2029 --> Dec 2025

P=N/A, N=400, Enrolling by invitation, University of California, San Diego | Trial completion date: Jun 2027 --> Sep 2027 | Initiation date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2026 --> Sep 2026

P=N/A, N=527, Completed, University of Washington | Active, not recruiting --> Completed

The PN program, which used reminder texts and calls, alongside mass mailings of stool kits, increased kit returns over the implementation period.

P=N/A, N=5255, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Dec 2024

28% had positive findings on both upper and lower endoscopy and 6% had normal upper and lower endoscopy.ConclusionThis study suggests that UGI endoscopy may be a beneficial component of the workup for positive Cologuard tests in certain high-risk populations. This practice could identify significant pathology and improve early detection of conditions like peptic ulcers and early cancers, thereby enhancing patient outcomes.

FIT was the most cost-effective strategy for preventing CRC cases and deaths. At real-world adherence of 60%, mt-sRNA demonstrated the greatest clinical benefit and was more cost-effective than other molecular strategies.

High-performance, candidate ctDNA biomarker panels with exceptional diagnostic accuracy for both CRC and APL have been identified. Further work should focus on the development of large-scale studies to justify their clinical implementation.